Ansell's (ASX:ANN) raised earnings guidance was helped by its sales tracking well, US trades in line with expectations, and margins expansion as KBU cost synergies and manufacturing productivity initiatives were realized and foreign exchange moved favourably, said Jefferies in a Wednesday note.

The company on Wednesday said it expects adjusted earnings per share in the range of $1.37 to $1.49 in fiscal year 2026, up from its previous guidance in the range of $1.33 to $1.45.

The investment firm added that the company's APIP and KBU divisions are delivering revenue and cost benefits, and progress has been made on pricing in tariffs to date.

Jefferies believes that if it assumes a 25% tariff were to apply to imported medical PPE from January 2026, Ansell would need to increase US medical product prices by about 10% in fiscal year 2026 and about 19% in fiscal year 2027 to maintain its net profit after tax.

Jefferies has maintained a buy rating on Ansell and increased its price target to AU$43 from AU$39.

The company's shares fell almost 1% in recent Thursday trade.